Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB00540_nanopub.RAdMK2WpHNLBugDBlU76ZG-VNHn8s3dY2Nz9wDgNalxgE#assertion>. }

• drugbank:DB00540 type drugbank_vocabulary:Drug assertion.
• drugbank:DB00540 label "Nortriptyline [drugbank:DB00540]" assertion.
• drugbank:DB00540 seeAlso nortrip.htm assertion.
• drugbank:DB00540 seeAlso nortriptyline.html assertion.
• drugbank:DB00540 seeAlso DB00540 assertion.
• drugbank:DB00540 description "Nortriptyline hydrochloride, the <i>N</i>-demethylated active metabolite of amitriptyline, is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, nortriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, nortriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H₁ receptors, α₁-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Nortriptyline exerts less anticholinergic and sedative side effects compared to the tertiary amine TCAs, amitriptyline and clomipramine. Nortriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use)." assertion.
• drugbank:DB00540 identifier "drugbank:DB00540" assertion.
• drugbank:DB00540 title "Nortriptyline" assertion.
• drugbank:DB00540 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46507783 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-pubchemcompound pubchem.compound:4543 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-chemspider chemspider:4384 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-cas cas:72-69-5 assertion.
• drugbank:DB00540 drugbank_vocabulary:drugbank-id "APRD00602" assertion.
• drugbank:DB00540 drugbank_vocabulary:drugbank-id "DB00540" assertion.
• drugbank:DB00540 bio2rdf_vocabulary:x-identifiers.org DB00540 assertion.
• drugbank:DB00540 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00540" assertion.
• drugbank:DB00540 bio2rdf_vocabulary:namespace "drugbank" assertion.
• drugbank:DB00540 bio2rdf_vocabulary:identifier "DB00540" assertion.
• drugbank:DB00540 drugbank_vocabulary:x-wikipedia wikipedia:Nortriptyline assertion.
• drugbank:DB00540 drugbank_vocabulary:x-pharmgkb pharmgkb:PA450657 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-kegg kegg:C07274 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-dpd dpd:2240789 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-chebi chebi:7640 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-atc atc:N06AA10 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-ahfs ahfs:28:16.04.28 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-ndc ndc:54868-2835-2 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-iuphar iuphar:2404 assertion.
• drugbank:DB00540 drugbank_vocabulary:x-gtp gtp:2404 assertion.